SEC Filing Summary: Landec Corporation (8-K)
Business Context and Reporting Period
This Form 8-K was filed by Landec Corporation (not Lifecore Biomedical, Inc., which is a client mentioned in the report) on May 17, 2021. The filing serves as a Regulation FD disclosure regarding a press release issued on the same date.
Key Financial Metrics
The filing text does not provide specific financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. This report is a current event disclosure rather than a periodic financial statement.
Material Changes and Events
- Regulatory Approval: Heron Therapeutics, Inc. received U.S. regulatory approval for a new treatment of postoperative pain.
- Company Role: Landec Corporation provided Contract Development and Manufacturing Organization (CDMO) support for the approved treatment.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, management commentary on future performance, or specific risk factors beyond the standard disclaimer that the information is furnished and not "filed" for purposes of Section 18 of the Exchange Act.
Investor Verification Checklist
- Verify the commercial terms of the CDMO agreement between Landec and Heron Therapeutics.
- Confirm the expected revenue impact of the Heron Therapeutics regulatory approval on Landec's future quarters.
- Review the full text of the press release (Exhibit 99.1) for details on the specific drug and approval scope.